Neurocrine Biosciences

US · NBIX #1162 by market cap Listed 1970

143.47 -2.04 -1.40%

Live - 5344 symbols - heartbeat 47s ago · 2026-10-08 04:01

Pre-market 143.47 0.00%

After-hours 143.47 0.00%

Overnight 143.47 0.00%

Market cap: 14.58B
P/E (TTM): 20.98
P/B: 3.95
EPS: 4.67
Div yield: 0.00%
52W pos: 33%

Reader sentiment Are you bullish or bearish on NBIX?

Anonymous reader poll. Unscientific, not investment advice.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Founded: 1992
CEO: Dr. Kyle W. Gano, PhD
Employees: 2,000
Headquarters: San Diego, California, United States of America
Fiscal year end: 12-31
Website: neurocrine.com

Company profile

Exchange: US
Symbol: NBIX
Market-cap rank: #1162
Listing date: 1970-01-01
Market cap: 14.58B
Float cap: 14.40B
Shares out: 101.65M
Float shares: 100.37M

Sectors & themes

Drug Manufacturers - Specialty & Generic Global medical industry Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 04:01:04 · For reference only, not investment advice and not tailored to your situation.